EMA Refused: Zelnorm (tegaserod) — Novartis Europharm Limited

View source ↗

Summary

The EMA refused the marketing authorization for Zelnorm (tegaserod) by Novartis Europharm Limited for irritable bowel syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Irritable Bowel Syndrome

Drugs mentioned

• Zelnorm (tegaserod)

Snippet

Status: Refused. Therapeutic area: Irritable Bowel Syndrome. MAH: Novartis Europharm Limited. Decision date: 31/12/2009